Home
 /
Papers
 /
Neuroscience
 /
Metabolic reallocation in spinal cord oligodendrocytes drives chronic pain via neuronal β-amyloid production
Preprint
Open access
V1
Top 1% · Validated by QED

Metabolic reallocation in spinal cord oligodendrocytes drives chronic pain via neuronal β-amyloid production

Yannick Fotio, Saeed Al Masri, Zechuan Shi +7 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.01.23.701389
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Neuroscience this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

This paper overturns the assumption that amyloid-β pathology belongs exclusively to neurodegeneration, showing that peripheral injury reprograms spinal oligodendrocyte metabolism to drive neuronal Aβ release—making secretase and NAAA inhibition viable strategies for chronic pain.

QED claims analysis

Summary

Peripheral injury triggers metabolic reprogramming in spinal oligodendrocytes that redirects lipids from myelin maintenance to neuroplastic remodeling, disrupting axonal integrity and driving neuronal β-amyloid production through a NAAA-dependent pathway that is both necessary and sufficient for the transition from acute to chronic pain.

See full analysis
Main Claim 1 –

Peripheral Injury Reprograms Metabolism in Spinal Oligodendrocytes

Supporting evidence

  • Oligodendrocytes Reroute Lipids from Myelin to Gray Matter
Main Claim 2 –

Peripheral Injury Induces Spinal β-Amyloid Production

Supporting evidence

  • Myelin Lipid Loss Impairs Axons and Accumulates Neuronal APP
Main Claim 3 –

Spinal β-Amyloid Release Is Required for Chronic Pain

Supporting evidence

  • Blocking Aβ Production Genetically or Pharmacologically Prevents Chronic Pain
Main Claim 4 –

Oligodendrocyte NAAA Drives β-Amyloid Production and Pain Chronification

Supporting evidence

  • NAAA Inhibition Restores Oligodendrocyte Myelin Gene Expression Programs

Abstract

Peripheral injury reprograms metabolism in spinal cord oligodendrocytes, initiating a molecular cascade that drives chronic pain via neuronal β-amyloid (Aβ) release. After injury, mouse spinal oligodendrocytes downregulate myelin protein synthesis and upregulate lipid biosynthesis—but reroute lipids toward neuroplastic remodeling and away from myelin maintenance. This metabolic reallocation disrupts myelin integrity and axonal function, causing neuronal accumulation of amyloid precursor protein, enhanced expression of its processing β-secretase BACE1, and local release of Aβ peptides. Blocking Aβ production or clearing Aβ deposits stops the transition to pain chronicity. Deleting the lysosomal lipid hydrolase NAAA in oligodendrocytes prevents both injury-induced Aβ production and chronic pain development. The findings identify an unexpected mechanistic link between chronic pain and Alzheimer’s-like neurodegeneration, positioning Aβ as a target for therapeutic intervention.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?